Communication
Version 1
Preserved in Portico This version is not peer-reviewed
Evaluating Hypericin as a Therapeutic Agent Against Neisseria gonorrhoeae
Version 1
: Received: 9 February 2024 / Approved: 12 February 2024 / Online: 12 February 2024 (05:35:59 CET)
How to cite: Ferrari, I. V. Evaluating Hypericin as a Therapeutic Agent Against Neisseria gonorrhoeae. Preprints 2024, 2024020636. https://doi.org/10.20944/preprints202402.0636.v1 Ferrari, I. V. Evaluating Hypericin as a Therapeutic Agent Against Neisseria gonorrhoeae. Preprints 2024, 2024020636. https://doi.org/10.20944/preprints202402.0636.v1
Abstract
Neisseria gonorrhoeae is a bacterium that causes the sexually transmitted infection gonorrhea. This study employed molecular docking simulations to investigate potential interactions between natural molecules and the Fe(3+) ions import ATP-binding protein fbpC in Neisseria gonorrhoeae FA 1090. Among the screened molecules, Hypericin exhibited a remarkable binding energy of approximately -13.2 kcal/mol, indicating a robust and favorable binding affinity with the target protein. This promising outcome suggests that Hypericin could serve as a potential candidate for further exploration as a therapeutic agent against Neisseria gonorrhoeae infections. However, it is imperative to emphasize that these in silico findings necessitate experimental validation through in vitro and in vivo studies to ascertain the actual efficacy and safety of Hypericin as a treatment option.
Keywords
Hypericin; Neisseria gonorrhoeae; Docking analysis; Autodock Vina
Subject
Public Health and Healthcare, Public, Environmental and Occupational Health
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment